Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) was the target of a large drop in short interest in September. As of September 15th, there was short interest totaling 38,427 shares, a drop of 88.7% from the August 31st total of 340,186 shares. Based on an average daily trading volume, of 136,492 shares, the short-interest ratio is presently 0.3 days. Currently, 4.4% of the company’s stock are sold short.
Analyst Ratings Changes
Several research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Valion Bio, Inc. Common Stock to a “hold” rating in a research note on Saturday, September 5th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.
Get Our Latest Stock Analysis on Valion Bio, Inc. Common Stock
Valion Bio, Inc. Common Stock Stock Down 12.9%
Valion Bio, Inc. Common Stock Company Profile
Tivic Health Systems Inc operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc was incorporated in 2016 and is headquartered in Hayward, California.
See Also
- Five stocks we like better than Valion Bio, Inc. Common Stock
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
